Professor, MIT Sloan School of Management
Co-Founder, VP of Technology, Entropic Communications
President and CEO, BayBio
CEO, ActiveRain
President and CEO, Regulus Therapeutics
Managing Director, Mobile Ecosystem
Chairman, CEO, & Founder, Alexandria Real Estate Equities
Managing Director, DaggerBoard Advisors
|
|
A smattering of fundraising announcements involving Boston-area companies and investors, along with a student entrepreneurship program in this collection of local news tidbits:
—Skyword, a Boston-based marketing company that links freelance copywriters with advertisers and other clients, has raised... Read more »
For cities to truly thrive in this economy, fresh ideas must be cross-pollinated from beyond their borders—and New York offers its share of honey to lure in startups. This international gateway can be the place for companies to break into the... Read more »
No question, traders in the stock market knew there was going to be an appetite for shares of data visualization provider Tableau Software. But that hunger for business-tech IPO stocks is even deeper than Tableau guessed.
Shares of the Seattle-based company (NYSE:... Read more »
I was pretty slow about getting around to reading Thinking, Fast and Slow. The career-capping book by Princeton psychologist Daniel Kahneman, one of the founders of behavioral economics, spent months on all the bestseller lists back in 2011. I finally... Read more »
Few could accuse XBiotech CEO John Simard of failing to think big.
The Austin, TX-based startup he founded in 2005 is testing a novel biological drug candidate that is aiming to treat the persistent inflammation that makes cancer patients feel so... Read more »
[Clarification 5/17/13, 2:05 pm. See below.] Right on the same line with the original lede so you don’t waste space on a carriage return…Antibody drugs seemed to be the topic of the week for San Diego’s life sciences community.... Read more »
Wall Street’s hunger for business-tech companies is on display again with the initial public offering of Seattle-based Tableau Software.
Tableau, a provider of data-visualization software, begins trading today (NYSE: DATA) at $31 per share. That’s a higher price than... Read more »
All eyes in the biotech world will soon turn to the American Society of Clinical Oncology’s annual meeting in Chicago, but for now, the industry keeps humming along. This week’s news was highlighted by partnerships, product launches and big name hirings—and... Read more »
Science news often falls into the trap of becoming “infotainment” designed to generate ratings, and little else. As one essayist in The Guardian recently put it, “freaky copulation techniques in the animal kingdom,” heart-warming tales of miracle cures for kids, or... Read more »
The Boston area’s best-known startup hub is taking another big step in its national expansion plans.
The Cambridge Innovation Center, an all-in-one office space and services provider that houses some 500 companies near the MIT campus, is opening a branch... Read more »
AnaptysBio says today the U.S. government has asked the San Diego biotech to produce antibodies that counter the deadly effects of ricin and would not require refrigeration, so batches of anti-ricin antibodies could be stored at room temperatures.
Under a contract... Read more »
Ninepoint Medical earned the distinction of becoming the first—and to date, the only—medical device maker seeded by startup creation specialist Third Rock Ventures when it set up shop in 2009. Some four years and $33 million later, Ninepoint’s vision, a product... Read more »
San Diego’s Ambit Biosciences cut the share price of its planned IPO by nearly half yesterday, but still managed to raise about $65 million by increasing the number of shares in its debut offering. Shares of the biopharmaceutical company began trading... Read more »
First of all, the company is no longer called the Daily Grommet. Now it’s just The Grommet.
“We still execute daily,” says CEO Jules Pieri, “but we dropped the word because it seemed to be superfluous.” She adds, “We love... Read more »
When Tel Aviv, Israel-based PrimeSense came out with its first depth-sensitive, near-infrared camera-on-a-chip in 2010, nobody could have predicted how many uses hardware makers would dream up for the technology within a few short years.
The first and most famous was... Read more »
After much clamor about becoming a sanctuary for startups, New York faces the “now what?” stage of its growth as a tech hub.
Plans have been laid down to fill the streets with engineers—in another decade or two. But... Read more »
Matrix Genetics is one of those startups that never really got off the ground in its early days, but never died, either. While the Seattle-based company lived on fumes at various points over the past four years, it saw other contenders... Read more »
Less than a decade after being hatched out of a Texas university, Houston-based Bellicum Pharmaceuticals is in the midst of clinical trials on two innovative cancer therapies that, if successful, could result in new ways of attacking and killing off harmful... Read more »
It’s been almost two years since Paul Grayson was named as CEO of San Diego’s Anaphore—more than enough time for the former Fate Therapeutics CEO to put a new strategy in place.
The company unveiled the first element of its new... Read more »
Professor of Chemistry, Tufts University
Chief of Genetics, UC San Diego School of Medicine
CEO and Fund Manager, Renaissance Venture Capital Fund
Dean, College of Engineering, University of Washington
Founder and Managing Partner, Boston Millennia Partners
San Francisco · 6/3/13
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
